multiple system atrophy

Happy to be here.

For investors new, uh, to the company, can you give us an overview and the challenge of multiple system atrophy, and what ATH434 is being developed to do?

Yes.

So, um, Alterity is, is you mentioned, is an Australian, um, headquartered company, and we have a longstanding interest in developing, uh, novel treatments for treating neurodegenerative diseases.

Our lead indication, um, as you mentioned, is called multiple system atrophy, or MSA for short, and MSA is a, um, a rare disease.

It's referred to as a Parkinsonian disorder, um, which means early on it presents like Parkinson's disease, but the other side of the coin is that it, it, it progresses very rapidly, much more like ALS.

So in a way, um, it's- it's- it's better to think of it as a very aggressive, uh, disease, um, that, that looks like Parkinson's disease early on.

Now, our drug, um, ATH434, um, is a small molecule drug, uh, meaning it can be taken by a tablet and, and orally absorbed, and, um, we are developing that to try and slow the progression of multiple system atrophy.

So we took a quick break.

We were talking to Dr. Patel in our previous episode about MSA versus PD versus PSP.

So kind of like all the different variations that things that can look like Parkinson's.

Now we want to talk about the difference between the differences with dementia.

But that's not Louie Boddy.

Lewy body is, you can have that, but you have that much earlier.

So usually if you're gonna think about Lewy body disease is either they're having memory issues before they started having their motor symptoms or they had their motor symptoms and usually within the first four or five years, just like differentiating MSA, PSP, Parkinson's, Lewy body's looped into that category is that within the first four or five years of diagnosis or before their motor symptoms, they're going to start realizing that they're already hallucinating.

They're having memory issues.